THE Pride of St Helens Awards, sponsored by Mikhail Hotel & Leisure Group, will take place on Friday, November 22.

Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share price.

The company saw its stock drop by nearly 35% after reporting the data on 11 November. Image credit: Shutterstock / eamesBot Neurogene’s stock has dropped by nearly 35% in pre-market trading after a ...

Neurogene Inc. on Monday released Phase I/II data for its investigational gene therapy NGN-401, touting “consistent, concordant and durable” symptom improvements in patients with Rett syndrome.

June 13, 2024 — A viral gene therapy has reversed some brain abnormalities in infant mice with FOXG1 syndrome, a significant step toward one day treating children with this severe neurodevelopmental ...

A Neurogene gene therapy in development for the rare neurodevelopmental disorder Rett syndrome has encouraging early data in a small group of patients, an interim readout that comes a week after a ...

The big pharma company retained an option to license European rights to bardoxolone in other indications – including autosomal dominant polycystic kidney disease (ADPKD), genetic disease Alport ...

Nov. 12, 2024 — Researchers have found that the way DNA is packaged in cells can directly impact how fast DNA itself is copied during cell division. They discovered that DNA packaging sends ...

A researcher from The University of Manchester has bagged a prize for developing a powerful way to minimize suffering in animals when studying kidney ...